biotech / news / / CNBC TV18
Gujarat Themis to acquire Sanofi anti-TB portfolio for €158 million.
Gujarat Themis Biosyn will acquire Sanofi's anti-TB and anti-infective brands for €158 million.
KEY POINTS
- The acquisition covers 13 branded generic products sold in over 55 countries across EMEA regions.
- GTBL will not acquire any manufacturing facilities, legal entities, or employees in the transaction.
- The acquired portfolio's net sales declined from €67 million in FY24 to €62 million in FY25.
- The deal enables GTBL to access regulated and semi-regulated markets and integrate APIs with finished products.
COMPANIES
Summarized by Newsio from CNBC TV18. How we summarize →